---
layout: default
title: Papain
parent: Model Prediction Only (L5)
nav_order: 644
evidence_level: L5
indication_count: 10
last_modified_at: 2026-10-14
description: "Papain: predicted new indication Primary release disorder of platelets (evidence level L5). Approved use: Not stated in the available data"
monitor_inn: "Papain"
predicted_indications: ["primary release disorder of platelets", "Glanzmann thrombasthenia", "pseudo-von Willebrand disease", "HER2 positive breast carcinoma", "progesterone-receptor positive breast cancer", "normal breast-like subtype of breast carcinoma", "breast tumor luminal A or B", "progesterone-receptor negative breast cancer", "deafness, autosomal dominant 39, with dentinogenesis imperfecta 1", "rectal cloacogenic carcinoma"]
---

# Papain
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Papain: From an Unspecified Original Indication to Primary Release Disorder of Platelets

## One-Sentence Summary

Papain is a cysteine protease enzyme marketed in India as a topical ointment, but the data compiled for this report do not state its approved indication.
The TxGNN model predicts it may be effective for **primary release disorder of platelets**, with a high score, yet **no clinical trials** and **only 1 loosely related publication** support this direction.
The prediction rests on model output alone and is not backed by clinical or mechanistic evidence.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the available data |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 98.22% |
| Evidence Level | L5 |
| India Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, papain is a cysteine protease (an enzyme that cleaves proteins). It is marketed in India as a single-ingredient ointment, but the approved indication is not recorded in the data compiled for this report.

Papain can cleave platelet surface glycoproteins in vitro, so a theoretical effect on platelet function exists. However, such changes would be expected to impair rather than restore platelet function, so the therapeutic direction is doubtful.

The only retrieved paper (PMID 38430019) compares two types of platelet-rich plasma for cartilage repair in a rabbit osteoarthritis model. It does not involve papain and does not address platelet release disorders. The high TxGNN score is therefore not supported by clinical or mechanistic evidence.

Other top-ranked predictions show the same pattern:
- **Glanzmann thrombasthenia (98.06%)**: two in vitro papers use papain-treated platelets as a research tool. They show no therapeutic effect.
- **Pseudo-von Willebrand disease (97.78%)**: no literature or trials.
- **HER2-positive breast carcinoma (97.44%)**: papain appears only as the enzyme used to prepare antibody Fab fragments. It has no shown anti-tumour activity.
- **Other breast cancer subtypes, a rare genetic hearing/dental disorder, and rectal cloacogenic carcinoma**: no supporting evidence, likely knowledge-graph artifacts.

## India Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| Registration No. 58693 | Debrifree Ointment (Torrent Pharmaceuticals Ltd) | Tube of 15 gm ointment | Not stated in the available data |

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [38430019](https://pubmed.ncbi.nlm.nih.gov/38430019/) | 2024 | Preclinical (animal) | Cellular and Molecular Biology | Compares leukocyte-rich and leukocyte-poor platelet-rich plasma on cartilage in rabbit osteoarthritis. Unrelated to papain. |

## Safety Considerations

Please refer to the package insert for safety information. No drug interaction records were found for papain in the data compiled for this report.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no clinical trials and no relevant literature (Evidence Level L5). The only retrieved paper is unrelated to papain, and the proposed direction (papain altering platelet surface proteins) would more plausibly impair than improve platelet function. All other top-10 predictions are equally unsupported.

**To proceed, the following is needed:**
- The approved indication and package insert (warnings and contraindications) for Debrifree Ointment from the Indian regulator or manufacturer
- Mechanism of action data for papain
- Direct preclinical evidence that papain has a therapeutic, not just a research-tool, effect on platelet release disorders
- A review of whether another predicted indication has a more credible mechanistic basis, given that this one does not
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

